These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16730335)

  • 1. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.
    Anderson GM; Scahill L; McCracken JT; McDougle CJ; Aman MG; Tierney E; Arnold LE; Martin A; Katsovich L; Posey DJ; Shah B; Vitiello B
    Biol Psychiatry; 2007 Feb; 61(4):545-50. PubMed ID: 16730335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.
    Troost PW; Lahuis BE; Steenhuis MP; Ketelaars CE; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2005 Nov; 44(11):1137-44. PubMed ID: 16239862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
    Yasui-Furukori N; Saito M; Tsuchimine S; Nakagami T; Sato Y; Sugawara N; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1491-5. PubMed ID: 18579277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.
    Malone RP; Maislin G; Choudhury MS; Gifford C; Delaney MA
    J Am Acad Child Adolesc Psychiatry; 2002 Feb; 41(2):140-7. PubMed ID: 11837403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.
    Troost PW; Lahuis BE; Hermans MH; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
    J Clin Psychopharmacol; 2007 Feb; 27(1):52-7. PubMed ID: 17224713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.
    McDougle CJ; Scahill L; McCracken JT; Aman MG; Tierney E; Arnold LE; Freeman BJ; Martin A; McGough JJ; Cronin P; Posey DJ; Riddle MA; Ritz L; Swiezy NB; Vitiello B; Volkmar FR; Votolato NA; Walson P
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):201-24. PubMed ID: 10674197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.
    Correia CT; Almeida JP; Santos PE; Sequeira AF; Marques CE; Miguel TS; Abreu RL; Oliveira GG; Vicente AM
    Pharmacogenomics J; 2010 Oct; 10(5):418-30. PubMed ID: 19997080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the Taq1A variant in the dopamine Dâ‚‚ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
    Roke Y; van Harten PN; Franke B; Galesloot TE; Boot AM; Buitelaar JK
    Pharmacogenet Genomics; 2013 Sep; 23(9):487-93. PubMed ID: 23851570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.
    Akhondzadeh S; Fallah J; Mohammadi MR; Imani R; Mohammadi M; Salehi B; Ghanizadeh A; Raznahan M; Mohebbi-Rasa S; Rezazadeh SA; Forghani S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):32-6. PubMed ID: 19772883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
    Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
    Pharmacogenet Genomics; 2007 Nov; 17(11):989-93. PubMed ID: 18075468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone: new indication. Behavioural disorders in children with autism or mental disabilities: no progress.
    Prescrire Int; 2006 Apr; 15(82):43-5. PubMed ID: 16602211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.
    Haas M; Delbello MP; Pandina G; Kushner S; Van Hove I; Augustyns I; Quiroz J; Kusumakar V
    Bipolar Disord; 2009 Nov; 11(7):687-700. PubMed ID: 19839994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.
    Sukasem C; Hongkaew Y; Ngamsamut N; Puangpetch A; Vanwong N; Chamnanphon M; Chamkrachchangpada B; Sinrachatanant A; Limsila P
    J Clin Psychopharmacol; 2016 Apr; 36(2):141-6. PubMed ID: 26872113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone and cognitive function in children with disruptive behavior disorders.
    Pandina GJ; Bilder R; Harvey PD; Keefe RS; Aman MG; Gharabawi G
    Biol Psychiatry; 2007 Aug; 62(3):226-34. PubMed ID: 17210137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study.
    Lindsay RL; Eugene Arnold L; Aman MG; Vitiello B; Posey DJ; McDougle CJ; Scahill L; Pachler M; McCracken JT; Tierney E; Bozzolo D
    J Intellect Dev Disabil; 2006 Dec; 31(4):204-9. PubMed ID: 17178532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone and liver function tests in children and adolescents: a short-term prospective study.
    Erdogan A; Atasoy N; Akkurt H; Ozturk D; Karaahmet E; Yalug I; Yalug K; Ankarali H; Balcioglu I
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):849-57. PubMed ID: 18258348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
    Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
    J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.
    Duval F; Guillon MS; Mokrani MC; Crocq MA; Garcia Duarte F
    Psychoneuroendocrinology; 2008 Feb; 33(2):255-9. PubMed ID: 18053652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.
    Calarge CA; Ellingrod VL; Acion L; Miller DD; Moline J; Tansey MJ; Schlechte JA
    Pharmacogenet Genomics; 2009 May; 19(5):373-82. PubMed ID: 19339912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.